Mohsin Md, Mahmud Sultan, Uddin Mian Ashraf, Hasan Prottay, Muyeed Abdul, Taif Ali Md, Faysal Ahmed Fee, Islam Ariful, Maliha Rahman Maisha, Islam Mahfuza, Rahaman Khan Md Hasinur, Shafiqur Rahman M
Institute of Statistical Research and Training, University of Dhaka, Dhaka 1000, Bangladesh.
International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B), Dhaka 1212, Bangladesh.
Vaccine X. 2022 Dec;12:100207. doi: 10.1016/j.jvacx.2022.100207. Epub 2022 Aug 22.
One of the primary reasons for hesitancy in taking COVID-19 vaccines is the fear of side effects. This study primarily aimed to inspect the potential side effects of the COVID-19 vaccines circulated in Bangladesh.Design and Settings.The study was based on a cross-sectional anonymous online survey conducted in December 2021 across Bangladesh.Participants.The study included consenting Bangladeshi individuals aged 12 and above who had received at least one dose of the COVID-19 vaccines.Main Outcome.Analyses were carried out through exploratory analysis, Chi-square test, and logistic regression to investigate potential side effects of the COVID-19 vaccines.
A total of 1,180 vaccinated people participated in the study. Only 39.48% of the participants reported at least one side effect after receiving their COVID-19 vaccine. Injection-site pain, fever, headache, redness/swelling at the injection site, and lethargy were the most commonly reported adverse effects, all of which were mild and lasted 1-3 days. Side effects were most prevalent (about 80%) among individuals who received Pfizer-BioNTech and Moderna vaccines and were least common among those who received Sinopharm and Sinovac vaccines (21%-28%). When compared to the Sinopharm vaccines, the OxfordAstraZeneca, Pfizer-BioNTech, and Moderna vaccines were 4.51 times (95% CI: 2.53-8.04), 5.37 times (95% CI: 2.57-11.22), and 4.28 times (95% CI: 2.28-8.05) likelier to produce side effects. Furthermore, males, those over 50 years old, urban dwellers, smokers, and those with underlying health issues had a considerably increased risk of developing side effects. A lack of confidence in vaccines' efficacy and a substantial level of hesitancy in allowing children (age five years or over) and older people (70 years or over) to receive COVID-19 vaccines were also observed.
Side effects of COVID-19 vaccines are minimal, demonstrating their safety. Efforts should be made to disseminate such findings worldwide to increase vaccine uptake.
对新冠疫苗接种犹豫不决的一个主要原因是担心副作用。本研究主要旨在调查在孟加拉国流通的新冠疫苗的潜在副作用。
设计与背景。该研究基于2021年12月在孟加拉国全国范围内进行的一项横断面匿名在线调查。
参与者。该研究纳入了年龄在12岁及以上、已接种至少一剂新冠疫苗且表示同意参与的孟加拉国个人。
主要结果。通过探索性分析、卡方检验和逻辑回归进行分析，以调查新冠疫苗的潜在副作用。
共有1180名接种疫苗的人参与了该研究。只有39.48%的参与者在接种新冠疫苗后报告了至少一种副作用。注射部位疼痛、发热、头痛、注射部位发红/肿胀和嗜睡是最常报告的不良反应，所有这些反应都很轻微，持续1 - 3天。在接种辉瑞 - 生物科技公司和莫德纳疫苗的人群中，副作用最为普遍（约80%），而在接种国药集团和科兴疫苗的人群中最不常见（21% - 28%）。与国药集团疫苗相比，牛津 - 阿斯利康、辉瑞 - 生物科技公司和莫德纳疫苗产生副作用的可能性分别高4.51倍（95%置信区间：2.53 - 8.04）、5.37倍（95%置信区间：2.57 - 11.22）和4.28倍（95%置信区间：2.28 - 8.05）。此外，男性、50岁以上的人、城市居民、吸烟者以及有基础健康问题的人出现副作用的风险大幅增加。还观察到对疫苗效力缺乏信心，以及在允许儿童（5岁及以上）和老年人（70岁及以上）接种新冠疫苗方面存在相当程度的犹豫不决。
新冠疫苗的副作用极小，证明了其安全性。应努力在全球传播此类研究结果，以提高疫苗接种率。
